alnylam plans to share the full data later this summer, and we'll be speaking with alnylam's ceo yvonne greenstreet later on "fast money" and will be asking her about these results. kelly? >> i'll pick it up there we're also getting some news from novo nordisk? tell us about that >> they're telling us they will spend $4.1 billion to build a new glp-1 manufacturing base here in the u.s. this will focus on making wegov and future drugs for obesity this is one of the largest manufacturing investments in its history. we're seeing an arms race between novo and lilly as they try to make as many of their glp drugs as they possibly can novo telling us that about 35,000 people in the u.s. are starting wegovy over week. that's up from 27,000 in may but it's important to remember that these sites take years to get up and running, so we won't see this investment have an effect right away. guys >> thanks very much. ang angelica, appreciate it. >> you got it. >>> still to come, the eu adopting new sanctions against russia, even on lng. that story is next hi, i'm sally. i'm from phoenix, arizona. i'm

i think some data we saw this morning indicates that the alnylam drug works on top of pfizer. well as those who haven't taken the drug. numbers sound roughly right to me. >> how much do you expect it will cost, and is it -- how does it -- didn't get into it in so much detail that we know how often you take it, how long you take it. what are the metrics there? >> yeah. these patients are basically on the drug chronically. this is a couple hundred thousand dollar treatment per year. numbers add up quickly and why the company this morning in its press release basically commented this is a multibillion dollar opportunity. i think most models are kicking out at least $4 billion to $6 billion in peak sales based on memory. maybe that goes up today because of totality of data. stock has been terrible most of the year. basically on the fact that this was such an overhang. we needed to get past it. finally here. so shares are up a lot, and i think they'll probably continue to trade pretty well. >> and it's expensive. could you see hms, whoever decides these types of things, if it's fat

government reportedly urges the doj to bring criminal charges into the giant >>> and later, shares of alnylam pharma up. the ceo will join us for an exclusive interview to talk about the drug and what this all means for the company. i'm melissa lee, coming to you live from studio b at the nasdaq on the desk tonight -- tim seymour, dan nathan, guy adami, and savita. welcome. >> thank you >> and we start off with a third day of massive losses for nvidia sliding 7% today the biggest drop since mid-april. worst three-day decline since december 2022. it is now down 16% from the record highs hit just last thursday, shedding half a trillion dollars of market cap in that time today's move dragging down the rest of the chip sector. all seeing outsized losses but the rest of wall street seemed to shrug off this weakness the dow gaining more than 260 points, while the s&p 500 closed around the flat line so, this fear we had that the break in nvidia would take down the entire market, is that turning out to not be the case guy? >> one day does not a trend make, melissa, as you know but we flagged this las

both lilly and novo touching headlines and alnylam, a 6% gain after yesterday's 35% move higher at theay. what do we want to trade now? guy? >> tim alluded to it yesterday. just in the math of eli lilly and this has been true in for a while. it's done $52 million in revenue, by comparison merck will do $68 billion and one-third the size. there's something a skew here. i'm not saying sell eli lilly, and there will never be equals in this environment and merck given that math is still the stock you want to own. it's at an all-time high. >> the two have united into one story today. ai and weight loss. >> here's a question for you because i saw this great doc a few months ago on cnbc called big shy. >> you can watch it. >> when you see it, wegovy, it doesn't matter because it won't be there for years and they don't have the supplies. i'm curious, how do you think about that? if that's the thing driving price performance today, and it gives you greater confidence in the future and i'm sure there are chinese manufacturers working on this. >> or an oral readout later. there will be other drug

that should be enough to get the drug approved, and help alnylam get approval bridge bio is down, anothering is resmed an eli lilly showed promise for a sleep apnea drug it makes the cpap machines also. it is important to know that this trial looked only at people with obesity at this point, the drug wouldn't be used moor broadly >> thank you for bringing us the highlights time now for a news update with bertha coombs. >>> the supreme court announced it's taking up the issue of transgender rights, agreeing to hear a biden administration appeal looking to block stale bans on gender-affirming care. this involves a tennessee law that restricts puberty blockers and hormone therapy. >>> benjamin netanyahu says the intensive phase of fighting in gaza will end soon, and that will allow a shift in focus to the conflict with hezbollah on the northern border with lebanon. he also said he would only accept a partial cease-fire that would not end the war, appearing to move further away from a truce. >>> nearly three months after crashing into the key bridge in baltimore, "dolly" level port headed for